Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction.
about
Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic reviewKir6.2 is required for adaptation to stress.Cardiovascular safety of anti-diabetic drugsAlternative Medicine in Diabetes - Role of Angiogenesis, Oxidative Stress, and Chronic InflammationTreating the elderly diabetic patient: special considerationsImpact of hypoglycemic agents on myocardial ischemic preconditioningGlycemic control and cardiovascular disease: what's a doctor to do?The Influence of Diabetes Mellitus in Myocardial Ischemic PreconditioningPost-stenotic coronary blood flow at rest is not altered by therapeutic doses of the oral antidiabetic drug glibenclamide in patients with coronary artery diseaseRecent HbA1c values and mortality risk in type 2 diabetes. population-based case-control studyPro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence.Cardiovascular risk factor management of myocardial infarction patients with and without diabetes in the Netherlands between 2002 and 2006: a cross-sectional analysis of baseline dataAre hypoglycaemia and other adverse effects similar among sulphonylureas?Beating myocardium counteracts myogenic tone of coronary microvessels: involvement of ATP-sensitive potassium channels.Standard and Novel Treatment Options for Metabolic Syndrome and Diabetes MellitusIs the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysisDiabetes mellitus and coronary heart disease--from prevention to intervention: Part II.Impaired modulation of circadian rhythms in patients with diabetes mellitus: a risk factor for cardiac thrombotic events?Clinical review of glimepiride.Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition poreClinical relevance of ischemic preconditioning.Cardiovascular safety profile of currently available diabetic drugs.Understanding myocardial ischemic preconditioning, and the implications for a role of adenosine catabolism.Cardiac NO signalling in the metabolic syndrome.Diabetes and cardiovascular disease: the road to cardioprotection.Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?Type 2 diabetes mellitus and myocardial ischemic preconditioning in symptomatic coronary artery disease patients.Comparison of the micro- and macro-vascular effects of glimepiride and gliclazide in metformin-treated patients with Type 2 diabetes: a double-blind, crossover study.Reduction of cardiovascular morbidity and mortality in type 2 diabetes. A rational approach to hypoglycemic therapy.Pioglitazone and sulfonylureas: effectively treating type 2 diabetesChanging Patterns of Glucose-Lowering Medication Use in VA Nursing Home Residents With Diabetes, 2005 to 2011.Cardiac KATP channels in health and disease.Where do conventional OADs stand.Hyperglycemia and perioperative glucose management.Role of Kir6.2 subunits of ATP-sensitive potassium channels in endotoxemia-induced cardiac dysfunction.Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?Effectiveness of sulphonylureas in the therapy of diabetes mellitus type 2 patients: an observational cohort study.Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes.Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction.The role of glucose lowering agents on restenosis after percutaneous coronary intervention in patients with diabetes mellitus.
P2860
Q22242077-CDEFB429-3B22-4A04-A73C-2F3B3C289436Q24538695-949F33CC-2BA8-48A7-A925-88E19959BC9FQ26741082-CD709EA0-51A6-4B9F-ACAC-0977309B8FBFQ26801343-74B827D4-4C90-4E96-8792-72DC6A6AE762Q26995176-F53C0340-4C27-46DF-A109-27B4803D4838Q27014018-C54E0902-B5C1-4869-B5DE-6D0323AFC105Q27024469-AF6868DE-B511-4CC9-B706-6894F9E1CC5CQ28080349-93493C5F-C12A-47F9-A744-1DFFE256E712Q28343981-38ACB1A0-47D5-4093-BA7F-C6CA0ABCFCEFQ28534542-00D8717C-0EA8-4AE1-A2E5-FEE1ABF1CCBFQ30234356-4BB21062-B878-4394-A42B-F10ED87243E0Q30530802-F4B29AF2-4BDC-4981-9A91-3E1BE6C1C69CQ31122704-0AE75D64-22CD-4BEA-ADD8-8CDC500499FBQ33251446-5B8B0ADF-3795-4F28-BE10-36FBCEF7F3CFQ33618721-2100BB9A-90D8-4387-950B-57CC02BC7754Q33880174-4B1D0AC4-7D33-4B40-B634-5BDB6ADD0CA4Q34099605-CA23DC69-D8D6-41E3-AC25-9FD486EA0694Q34180071-4C56FC53-94B9-441B-ACD9-FC897D7AFD9AQ34240998-601259AD-291A-434F-8808-0549C6CD5E64Q34327908-47C4B16A-E5CB-4B6A-8669-5217827BB52AQ34523796-DA637A38-066E-4045-BAEB-8DEE05DEA830Q34971736-D11A378B-103A-4FCA-B9CD-294EDE07B7E1Q35072009-AA13B1D1-8D9E-4BCC-8232-E953336B8B4AQ35204828-A459DF3A-227D-4C9F-BAA2-8BF6C2FDB910Q35585114-7D96B098-BF69-4242-B75B-ED81C9649F1FQ35607945-F2380F89-EF9C-45DD-96F5-B99173B2E623Q35672947-ECBAEBB6-6CB0-47FB-BAD1-6BDF14C65209Q35825313-104C4924-EB5D-4B39-9291-76FF4F448091Q35847886-04DBB393-CC66-4F5A-BE10-356750F6DA1CQ35987456-70BB0553-A18B-4313-A612-3D89EE78AFBFQ36122492-F26923B6-909E-41AD-AD96-C9961CF0A256Q36135766-66BD9022-8F96-4FAD-BA4D-C6042288A09DQ36701092-D22119F4-6452-4A1B-9C24-9B74255D180EQ36810316-58EF9C88-1300-4FE9-9FB0-3554FB8C9197Q36846892-AB34BBFF-7E07-4E15-8C53-E747F51A15E0Q37107490-A4F0AD50-D279-4203-A96C-66D0EFBE08DCQ37145172-A5836910-20A3-4C95-A383-B687A8F2638CQ37145673-153897C2-38FC-49C7-AD5C-BA73CEAF79D8Q37148331-B8882B33-C9AB-440F-ADE7-0D328455352AQ37306857-DD0F4331-F47C-4330-9232-F46F628D518B
P2860
Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Sulfonylurea drugs increase ea ...... r acute myocardial infarction.
@en
Sulfonylurea drugs increase ea ...... r acute myocardial infarction.
@nl
type
label
Sulfonylurea drugs increase ea ...... r acute myocardial infarction.
@en
Sulfonylurea drugs increase ea ...... r acute myocardial infarction.
@nl
prefLabel
Sulfonylurea drugs increase ea ...... r acute myocardial infarction.
@en
Sulfonylurea drugs increase ea ...... r acute myocardial infarction.
@nl
P2093
P1476
Sulfonylurea drugs increase ea ...... r acute myocardial infarction.
@en
P2093
P304
P356
10.1016/S0735-1097(98)00557-9
P407
P577
1999-01-01T00:00:00Z